• Accelerating TB vaccine Research & Development through partnership
  • TBVI TBVI TBVI
    • Home
    • About us
      • TBVI at a glance
      • Mission
      • Organisation
        • Governance Board
        • Advisory Committee
        • Steering Committee
        • Operational Office
        • Product and Clinical Development Team
        • Portfolio Management Committee
      • TBVI consortium
      • Key achievements and impact
      • Financials
    • What we do
      • Pipeline of vaccines
      • Research & Development
      • Services
    • How we work
      • Business model
      • Partnership
    • For partners
      • For researchers and vaccine developers
        • Partners pages
        • Access to services
      • MTBVAC in Newborns
        • Coordinator and partners
        • News and Publications
        • Communication tools
      • MTBVACN3
        • Work packages
        • Governance
        • The consortium and its partners
        • Publications and news
        • Acknowledgement
      • TBVAC2020
        • Word from the chair
        • TBVAC2020 project overview and achievements
        • TBVAC2020 project members
        • TBVAC2020 scientific publications
        • TBVAC2020 other publications
      • For funders
        • TBVI R&D priorities and funding opportunities
        • TBVI service provision and funding opportunities
        • Why invest in TBVI
    • News
    • Contact us:

    Archives

    Monthly Archive for: "November, 2015"
    Home / 2015 / November
      0
    By Erna
    In Uncategorized Posted November 24, 2015

    ADITEC publications have broad and substantial impact on the future of vaccine research

    High quality vaccine research funded by the EUR 30 million FP7 High Impact Project on Advanced Immunization Technologies (ADITEC), in which TBVI is one of the partners, is confirmed by the [...]

    Read More
      0
    By Erna
    In News Posted November 17, 2015

    TB vaccine candidate shows excellent safety and promising immunogenicity

    Lausanne / Zaragoza / Madrid / Porriño / Lelystad, 17 November 2015 – For the first time, a live-attenuated tuberculosis vaccine – MTBVAC – has been evaluated in humans. MTBVAC – [...]

    Read More
    Load More
    Menu
    • Home
    • About us
    • What we do
    • How we work
    • For researchers and vaccine developers
    • For funders
    • Pipeline of vaccines
    • News
    TuBerculosis Vaccine Initiative (TBVI)

    Runderweg 6
    8219 PK Lelystad
    The Netherlands
    Email: info@tbvi.eu
    Phone: +31 320 277 550

    © 2015 TuBerculosis Vaccine Initiative (TBVI) | ALL RIGHTS RESERVED | Disclaimer | Sitemap | Door Internetbureau Redkiwi

    Start typing and press Enter to search

    Cookies

    This website uses cookies that help the website function

    OK No